The removal of the 12% management share grant is a clear positive for existing holders, reducing future dilution. Monitor the conversion terms of the Series A Convertible Preferred Stock to assess the remaining dilution risk from the acquisition consideration.
Price Chart
Executive Summary
Profusa Inc. amended its Asset Purchase Agreement with Bio Insights LLC to delete a provision that would have issued management shares equal to 12% of fully diluted common stock to the CEO and CFO upon closing. The $30 million acquisition of the PanOmics Assay platform proceeds unchanged, but the removal of this management equity grant eliminates a significant future dilution overhang for existing shareholders.
Key Financial Metrics
Key Facts
- Amendment dated May 22, 2026 removes Section 4.6 (Management Shares) from the Asset Purchase Agreement
- Previously, management would have received 12% of fully diluted shares post-closing and any related equity financing
- The $30 million aggregate purchase price for the PanOmics Assay assets remains unchanged
- Consideration is paid via Series A Convertible Preferred Stock (non-voting, convertible into common)
- All other terms of the April 21, 2026 Asset Purchase Agreement remain in full force
Financial Impact
Eliminates a 12% fully diluted share issuance to management, preserving equity value for existing shareholders. The $30 million purchase price via convertible preferred stock still creates potential future dilution upon conversion.
Risk Factors
- The $30 million Series A Convertible Preferred Stock still converts into common shares, creating dilution upon conversion
- No financial details on the PanOmics Assay's revenue or profitability were disclosed
- The ticker NVACW (warrants) may have different liquidity and risk profile than the common stock PFSA
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-060879 |
| Document: ea029215101ex10-1.htm | 0001213900-26-060879 |
| Document: 0001213900-26-060879-index-headers.html | 0001213900-26-060879 |
| Document: 0001213900-26-060879-index.html | 0001213900-26-060879 |
| Document: 0001213900-26-060879.txt | 0001213900-26-060879 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 8, 2026 20w ago | 8-K | — | awaiting T+20 | — | — |
May 26, 2026 21w ago | 8-K | — | awaiting T+20 | — | — |
May 15, 2026 23w ago | 8-K | — | awaiting T+20 | — | — |
May 8, 2026 24w ago | 8-K | — | awaiting T+20 | — | — |
May 1, 2026 25w ago | S-1/A | — | awaiting T+20 | — | — |
Apr 29, 2026 25w ago | 8-K | — | awaiting T+20 | — | — |
Apr 28, 2026 25w ago | S-1 | — | awaiting T+20 | — | — |
Apr 27, 2026 26w ago | 8-K | — | awaiting T+20 | — | — |
Apr 24, 2026 26w ago | 8-K | — | awaiting T+20 | — | — |
Apr 6, 2026 29w ago | 8-K | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers